Dynemic Products reported a consolidated profit of Rs 19.95 crore for FY 2025-26, up from Rs 15.00 crore in the previous year. The company announced a dividend of Rs 1.50 per share with an AGM set for September 28, 2026. Revenue grew to Rs 371.78 crore, reflecting steady demand in the specialty chemicals sector despite raw material price volatility.
Dynemic Products Annual Report FY 2025-26: Key Financials Revealed
Consolidated PAT: Rs 19.95 crore (vs Rs 15.00 crore in FY 24-25)
Dividend: Rs 1.50 per share (15% payout)
Reader Takeaway: Profit grew significantly on higher revenue, but shareholders must navigate proposed related party transactions at the AGM.
What just happened
Dynemic Products has released its Annual Report for FY 2025-26, highlighting a year of improved financial performance. The company posted a consolidated revenue of Rs 371.78 crore and a consolidated profit of Rs 19.95 crore. Shareholders will be offered a dividend of Rs 1.50 per share, with a record date for eligibility set for September 11, 2026.
Why this matters
The growth in bottom-line performance indicates the company’s ability to navigate volatile raw material costs in the specialty chemicals and food color segments. The proposed dividend reflects management's confidence in cash flows and commitment to returning value to retail investors.
Corporate Actions
The 36th Annual General Meeting is scheduled for September 28, 2026, via video conferencing. The board is seeking shareholder approval for specific related party transactions involving Mukesh B. Patel, a relative of the company's executive leadership. Investors should scrutinize these disclosures at the AGM to ensure alignment with corporate governance standards.
Risks to watch
Management noted ongoing challenges regarding global raw material price volatility and stricter regulations on synthetic colors. Additionally, the secretarial audit report highlighted minor procedural delays in filing, which the company claims are being addressed through remedial measures.
What to track next
Watch for the outcome of the AGM, specifically the shareholder vote on the proposed related party transactions and any additional management guidance regarding growth in the nutraceuticals segment for FY 2026-27.
